Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study

Fig. 2

Receiver operating characteristic curve analysis of tenascin (TNC) serum levels as a predictor of active systemic lupus erythematosus (defined as Systemic Lupus Erythematosus Disease Activity Index 2000 ≥ 6). At the optimal cutoff point of 659 ng/ml, the area under the curve for TNC serum levels that discriminated between active and inactive disease was 0.69 (95 % CI 0.53–0.86, p = 0.02) with a sensitivity of 53 % and specificity of 92 %

Back to article page